25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Avalo Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Avalo Therapeutics Inc together

I guess you are interested in Avalo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Avalo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Avalo Therapeutics Inc

I send you an email if I find something interesting about Avalo Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Avalo Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Avalo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.1%

What is your share worth?

Current worth
$1.95
Expected worth in 1 year
$2.50
How sure are you?
48.7%

+ What do you gain per year?

Total Gains per Share
$0.55
Return On Investment
5.2%

For what price can you sell your share?

Current Price per Share
$10.50
Expected price per share
$9 - $16.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Avalo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$10.50
Intrinsic Value Per Share
$-2.93 - $-2.00
Total Value Per Share
$-0.97 - $-0.05

2.2. Growth of Avalo Therapeutics Inc (5 min.)




Is Avalo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$21m-$2.3m-$16.3m-87.4%

How much money is Avalo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.9m-$8.2m$6.3m317.0%
Net Profit Margin1,955.3%-1,670.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Avalo Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#535 / 945

Most Revenue
#623 / 945

Most Profit
#302 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Avalo Therapeutics Inc?

Welcome investor! Avalo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Avalo Therapeutics Inc.

First you should know what it really means to hold a share of Avalo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Avalo Therapeutics Inc is $10.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avalo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avalo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.95. Based on the TTM, the Book Value Change Per Share is $0.14 per quarter. Based on the YOY, the Book Value Change Per Share is $0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avalo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.1420.3%-0.21-2.0%-0.75-7.2%-1.04-9.9%-0.71-6.8%
Usd Book Value Change Per Share2.1620.6%0.141.3%0.403.8%0.010.1%0.050.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.1620.6%0.141.3%0.403.8%0.010.1%0.050.5%
Usd Price Per Share9.50-13.21-1.82-4.51-3.53-
Price to Earnings Ratio1.11--0.49--0.56-0.20--0.53-
Price-to-Total Gains Ratio4.40--2.32--1.81-0.58-6.59-
Price to Book Ratio4.86--11.25--2.05--3.01-1.86-
Price-to-Total Gains Ratio4.40--2.32--1.81-0.58-6.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.5
Number of shares95
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.140.01
Usd Total Gains Per Share0.140.01
Gains per Quarter (95 shares)13.061.30
Gains per Year (95 shares)52.255.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10524214-5
2010494280
301571464125
4020919851610
5026125062015
6031330272420
7036635482825
8041840693230
90470458113635
100522510124040

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%5.034.00.012.8%5.034.00.012.8%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%10.010.00.050.0%19.020.00.048.7%19.020.00.048.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%2.00.037.05.1%2.00.037.05.1%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%10.010.00.050.0%19.020.00.048.7%19.020.00.048.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Avalo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.1600.137+1471%0.400+441%0.011+20184%0.050+4210%
Book Value Per Share--1.954-1.803+192%-0.226+112%0.917+113%0.736+165%
Current Ratio--1.4201.187+20%1.003+42%1.754-19%1.742-18%
Debt To Asset Ratio--0.7861.069-26%1.071-27%0.801-2%1.062-26%
Debt To Equity Ratio--3.6711.386+165%0.248+1381%1.257+192%2.201+67%
Dividend Per Share----0%-0%0.003-100%0.002-100%
Enterprise Value--106927351.500105568375.875+1%-2547120.600+102%35928320.301+198%29296192.714+265%
Eps--2.136-0.206+110%-0.754+135%-1.043+149%-0.710+133%
Ev To Ebitda Ratio---2.084-3.296+58%0.138-1606%-1.039-50%-1.100-47%
Ev To Sales Ratio--107.357infnan%-2.367+102%infnan%infnan%
Free Cash Flow Per Share---1.069-0.874-18%-0.762-29%-0.978-8%-0.642-40%
Free Cash Flow To Equity Per Share---1.0691.709-163%-0.162-85%0.244-539%0.093-1248%
Gross Profit Margin--1.0001.0000%1.0010%0.798+25%9.032-89%
Intrinsic Value_10Y_max---2.005--------
Intrinsic Value_10Y_min---2.926--------
Intrinsic Value_1Y_max---2.990--------
Intrinsic Value_1Y_min---2.938--------
Intrinsic Value_3Y_max---6.858--------
Intrinsic Value_3Y_min---6.590--------
Intrinsic Value_5Y_max---8.163--------
Intrinsic Value_5Y_min---7.760--------
Market Cap109867800.000+7%102448351.500138932875.875-26%19007129.400+439%47335562.101+116%37042546.589+177%
Net Profit Margin--92.51819.553+373%-16.701+118%-11.530+112%-7.519+108%
Operating Margin---51.651-16.590-68%-13.925-73%-17.019-67%-10.073-80%
Operating Ratio--52.65115.036+250%14.850+255%17.873+195%17.975+193%
Pb Ratio5.373+10%4.861-11.254+332%-2.050+142%-3.009+162%1.860+161%
Pe Ratio1.229+10%1.112-0.485+144%-0.561+150%0.201+452%-0.532+148%
Price Per Share10.500+10%9.50013.205-28%1.817+423%4.509+111%3.533+169%
Price To Free Cash Flow Ratio-2.456-11%-2.222-5.385+142%-0.970-56%-1.845-17%-2.997+35%
Price To Total Gains Ratio4.861+10%4.398-2.316+153%-1.808+141%0.583+654%6.593-33%
Quick Ratio--1.3661.120+22%0.918+49%1.741-22%1.659-18%
Return On Assets--0.234-0.057+124%-0.271+216%-0.218+193%-0.210+190%
Return On Equity--1.093-0.006+101%-0.089+108%-0.442+140%-0.803+173%
Total Gains Per Share--2.1600.137+1471%0.400+441%0.014+15628%0.052+4075%
Usd Book Value--21076000.000-18714000.000+189%-2364000.000+111%9623854.400+119%7721692.051+173%
Usd Book Value Change Per Share--2.1600.137+1471%0.400+441%0.011+20184%0.050+4210%
Usd Book Value Per Share--1.954-1.803+192%-0.226+112%0.917+113%0.736+165%
Usd Dividend Per Share----0%-0%0.003-100%0.002-100%
Usd Enterprise Value--106927351.500105568375.875+1%-2547120.600+102%35928320.301+198%29296192.714+265%
Usd Eps--2.136-0.206+110%-0.754+135%-1.043+149%-0.710+133%
Usd Free Cash Flow---11527000.000-9234000.000-20%-7977500.000-31%-10251988.200-11%-6727576.769-42%
Usd Free Cash Flow Per Share---1.069-0.874-18%-0.762-29%-0.978-8%-0.642-40%
Usd Free Cash Flow To Equity Per Share---1.0691.709-163%-0.162-85%0.244-539%0.093-1248%
Usd Market Cap109867800.000+7%102448351.500138932875.875-26%19007129.400+439%47335562.101+116%37042546.589+177%
Usd Price Per Share10.500+10%9.50013.205-28%1.817+423%4.509+111%3.533+169%
Usd Profit--23037000.000-1989499.750+109%-8297000.000+136%-10962335.850+148%-7454491.282+132%
Usd Revenue--249000.000205000.000+21%562500.000-56%1179842.150-79%2099541.410-88%
Usd Total Gains Per Share--2.1600.137+1471%0.400+441%0.014+15628%0.052+4075%
 EOD+5 -3MRQTTM+22 -15YOY+24 -145Y+22 -1710Y+19 -20

3.3 Fundamental Score

Let's check the fundamental score of Avalo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.229
Price to Book Ratio (EOD)Between0-15.373
Net Profit Margin (MRQ)Greater than092.518
Operating Margin (MRQ)Greater than0-51.651
Quick Ratio (MRQ)Greater than11.366
Current Ratio (MRQ)Greater than11.420
Debt to Asset Ratio (MRQ)Less than10.786
Debt to Equity Ratio (MRQ)Less than13.671
Return on Equity (MRQ)Greater than0.151.093
Return on Assets (MRQ)Greater than0.050.234
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of Avalo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.217
Ma 20Greater thanMa 5010.897
Ma 50Greater thanMa 10011.197
Ma 100Greater thanMa 20010.477
OpenGreater thanClose10.320
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-12-06 03:22:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Avalo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 9,251.8% means that $92.52 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avalo Therapeutics Inc:

  • The MRQ is 9,251.8%. The company is making a huge profit. +2
  • The TTM is 1,955.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9,251.8%TTM1,955.3%+7,296.5%
TTM1,955.3%YOY-1,670.1%+3,625.4%
TTM1,955.3%5Y-1,153.0%+3,108.3%
5Y-1,153.0%10Y-751.9%-401.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9,251.8%-109.4%+9,361.2%
TTM1,955.3%-221.4%+2,176.7%
YOY-1,670.1%-208.7%-1,461.4%
5Y-1,153.0%-346.2%-806.8%
10Y-751.9%-470.4%-281.5%
4.3.1.2. Return on Assets

Shows how efficient Avalo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • 23.4% Return on Assets means that Avalo Therapeutics Inc generated $0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avalo Therapeutics Inc:

  • The MRQ is 23.4%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -5.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ23.4%TTM-5.7%+29.1%
TTM-5.7%YOY-27.1%+21.5%
TTM-5.7%5Y-21.8%+16.2%
5Y-21.8%10Y-21.0%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.4%-11.6%+35.0%
TTM-5.7%-12.0%+6.3%
YOY-27.1%-11.2%-15.9%
5Y-21.8%-12.6%-9.2%
10Y-21.0%-14.2%-6.8%
4.3.1.3. Return on Equity

Shows how efficient Avalo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • 109.3% Return on Equity means Avalo Therapeutics Inc generated $1.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avalo Therapeutics Inc:

  • The MRQ is 109.3%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is -0.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ109.3%TTM-0.6%+109.9%
TTM-0.6%YOY-8.9%+8.3%
TTM-0.6%5Y-44.2%+43.5%
5Y-44.2%10Y-80.3%+36.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ109.3%-14.5%+123.8%
TTM-0.6%-16.0%+15.4%
YOY-8.9%-14.6%+5.7%
5Y-44.2%-18.6%-25.6%
10Y-80.3%-19.3%-61.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Avalo Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Avalo Therapeutics Inc is operating .

  • Measures how much profit Avalo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -5,165.1% means the company generated $-51.65  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avalo Therapeutics Inc:

  • The MRQ is -5,165.1%. The company is operating very inefficient. -2
  • The TTM is -1,659.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-5,165.1%TTM-1,659.0%-3,506.1%
TTM-1,659.0%YOY-1,392.5%-266.4%
TTM-1,659.0%5Y-1,701.9%+42.9%
5Y-1,701.9%10Y-1,007.3%-694.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,165.1%-203.3%-4,961.8%
TTM-1,659.0%-316.3%-1,342.7%
YOY-1,392.5%-216.5%-1,176.0%
5Y-1,701.9%-378.6%-1,323.3%
10Y-1,007.3%-480.3%-527.0%
4.3.2.2. Operating Ratio

Measures how efficient Avalo Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 52.65 means that the operating costs are $52.65 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 52.651. The company is inefficient in keeping operating costs low. -1
  • The TTM is 15.036. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ52.651TTM15.036+37.614
TTM15.036YOY14.850+0.186
TTM15.0365Y17.873-2.837
5Y17.87310Y17.975-0.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ52.6512.284+50.367
TTM15.0363.198+11.838
YOY14.8503.263+11.587
5Y17.8734.651+13.222
10Y17.9756.419+11.556
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Avalo Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.42 means the company has $1.42 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 1.420. The company is just able to pay all its short-term debts.
  • The TTM is 1.187. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.420TTM1.187+0.233
TTM1.187YOY1.003+0.184
TTM1.1875Y1.754-0.567
5Y1.75410Y1.742+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4203.601-2.181
TTM1.1873.872-2.685
YOY1.0034.655-3.652
5Y1.7545.973-4.219
10Y1.7426.258-4.516
4.4.3.2. Quick Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.37 means the company can pay off $1.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 1.366. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.120. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.366TTM1.120+0.245
TTM1.120YOY0.918+0.203
TTM1.1205Y1.741-0.621
5Y1.74110Y1.659+0.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3663.093-1.727
TTM1.1203.416-2.296
YOY0.9184.393-3.475
5Y1.7415.954-4.213
10Y1.6596.436-4.777
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Avalo Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Avalo Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Avalo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.79 means that Avalo Therapeutics Inc assets are financed with 78.6% credit (debt) and the remaining percentage (100% - 78.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 0.786. The company is just able to pay all its debts by selling its assets.
  • The TTM is 1.069. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ0.786TTM1.069-0.283
TTM1.069YOY1.071-0.003
TTM1.0695Y0.801+0.268
5Y0.80110Y1.062-0.261
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7860.345+0.441
TTM1.0690.346+0.723
YOY1.0710.311+0.760
5Y0.8010.365+0.436
10Y1.0620.382+0.680
4.5.4.2. Debt to Equity Ratio

Measures if Avalo Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 367.1% means that company has $3.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 3.671. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.386. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ3.671TTM1.386+2.285
TTM1.386YOY0.248+1.138
TTM1.3865Y1.257+0.129
5Y1.25710Y2.201-0.943
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6710.393+3.278
TTM1.3860.431+0.955
YOY0.2480.384-0.136
5Y1.2570.452+0.805
10Y2.2010.497+1.704
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Avalo Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 1.11 means the investor is paying $1.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avalo Therapeutics Inc:

  • The EOD is 1.229. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.112. Based on the earnings, the company is cheap. +2
  • The TTM is -0.485. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.229MRQ1.112+0.117
MRQ1.112TTM-0.485+1.597
TTM-0.485YOY-0.561+0.076
TTM-0.4855Y0.201-0.687
5Y0.20110Y-0.532+0.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.229-2.259+3.488
MRQ1.112-2.480+3.592
TTM-0.485-3.148+2.663
YOY-0.561-3.244+2.683
5Y0.201-5.991+6.192
10Y-0.532-6.692+6.160
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avalo Therapeutics Inc:

  • The EOD is -2.456. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.222. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.385. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.456MRQ-2.222-0.234
MRQ-2.222TTM-5.385+3.163
TTM-5.385YOY-0.970-4.415
TTM-5.3855Y-1.845-3.540
5Y-1.84510Y-2.997+1.152
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.456-2.995+0.539
MRQ-2.222-3.289+1.067
TTM-5.385-3.668-1.717
YOY-0.970-4.472+3.502
5Y-1.845-8.001+6.156
10Y-2.997-9.190+6.193
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Avalo Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.86 means the investor is paying $4.86 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avalo Therapeutics Inc:

  • The EOD is 5.373. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.861. Based on the equity, the company is fair priced.
  • The TTM is -11.254. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.373MRQ4.861+0.512
MRQ4.861TTM-11.254+16.115
TTM-11.254YOY-2.050-9.203
TTM-11.2545Y-3.009-8.245
5Y-3.00910Y1.860-4.868
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.3732.001+3.372
MRQ4.8612.054+2.807
TTM-11.2542.385-13.639
YOY-2.0502.431-4.481
5Y-3.0093.690-6.699
10Y1.8604.307-2.447
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avalo Therapeutics Inc.

4.8.1. Institutions holding Avalo Therapeutics Inc

Institutions are holding 64.989% of the shares of Avalo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Ikarian Capital, LLC9.27361.28549703599156291672.9929
2024-09-30Bvf Inc9.24150.26769670009670000
2024-09-30Deep Track Capital, LP9.24150.29149670009670000
2024-09-30Orbimed Advisors, LLC9.24150.16699670009670000
2024-09-30RA Capital Management, LLC9.24150.10599670009670000
2024-09-30Logos Global Management LP5.15190.552553907900
2024-09-30COMMODORE CAPITAL LP4.6160.28674830004430001107.5
2024-09-30TCG Crossover Management, LLC4.6160.38884830004830000
2024-09-30BOOTHBAY FUND MANAGEMENT, LLC1.56820.03551640921640920
2024-09-30Sio Capital Management, LLC0.68290.26927145800
2024-09-30Affinity Asset Advisors, LLC0.43010.05814500000
2024-09-30Vanguard Group Inc0.099101036800
2024-09-30Geode Capital Management, LLC0.0966010111101110
2024-09-30UBS Group AG0.058606134255171.1973
2024-06-30Bank of America Corp0.05350560156010
2024-09-30Tower Research Capital LLC0.00360.00013763760
2024-06-30BlackRock Inc0.00310329-1795-84.5104
2024-09-30Morgan Stanley - Brokerage Accounts0.0001010-10-50
2024-09-30Efficient Wealth Management LLC00550
2024-09-30BNP Paribas Arbitrage, SA00400
Total 63.61933.70816656926+5890560+88.5%

4.9.2. Funds holding Avalo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.09910.00011036800
2024-09-30Fidelity Extended Market Index0.04910.00015139-646-11.1668
2024-09-30Northern Trust Extended Eq Market Idx0.02310.0003241200
2024-09-30NT Ext Equity Mkt Idx Fd - L0.02310.0003241200
2024-09-30Fidelity Total Market Index0.01650172900
2024-09-30Spartan Extended Market Index Pool E0.01060.0002111211120
2024-09-30Fidelity Series Total Market Index0.00990103200
2024-09-30Fidelity Nasdaq Composite Index0.0072075800
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00360.000337210.2695
2024-09-30Spartan Total Market Index Pool E0.0033034100
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.000201900
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.000101500
2024-09-30BNYM Mellon SL Market Completion UC10.000101300
2024-10-31State St US Extended Mkt Indx NL Cl C0.000101200
2024-06-30SSgA U.S. Total Market Index Strategy005266.6667
2024-10-31State St US Ttl Mkt Indx SL Cl I00400
2024-09-30Northern Trust Wilshire 500000300
2024-09-30BNYM Mellon NSL Mkt Completion Fund Inst00100
Total 0.2460.001325747+469+1.8%

5.3. Insider Transactions

Insiders are holding 5.857% of the shares of Avalo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-12June Sherie AlmenoffBUY50012.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets98,455
Total Liabilities77,379
Total Stockholder Equity21,076
 As reported
Total Liabilities 77,379
Total Stockholder Equity+ 21,076
Total Assets = 98,455

Assets

Total Assets98,455
Total Current Assets86,148
Long-term Assets12,307
Total Current Assets
Cash And Cash Equivalents 81,858
Net Receivables 998
Other Current Assets 3,292
Total Current Assets  (as reported)86,148
Total Current Assets  (calculated)86,148
+/-0
Long-term Assets
Property Plant Equipment 1,674
Goodwill 10,502
Long-term Assets Other 131
Long-term Assets  (as reported)12,307
Long-term Assets  (calculated)12,307
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities60,674
Long-term Liabilities16,705
Total Stockholder Equity21,076
Total Current Liabilities
Short-term Debt 550
Accounts payable 1,811
Other Current Liabilities 58,313
Total Current Liabilities  (as reported)60,674
Total Current Liabilities  (calculated)60,674
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)16,705
Long-term Liabilities  (calculated)0
+/- 16,705
Total Stockholder Equity
Common Stock10
Retained Earnings -334,924
Other Stockholders Equity 354,332
Total Stockholder Equity (as reported)21,076
Total Stockholder Equity (calculated)19,418
+/- 1,658
Other
Cash and Short Term Investments 81,858
Common Stock Shares Outstanding 10,784
Liabilities and Stockholders Equity 98,455
Net Debt -81,308
Net Working Capital 25,474
Short Long Term Debt Total 550



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
12,317
9,170
7,582
5,451
21,658
16,929
13,172
9,583
5,769
3,561
6,048
28,204
43,124
62,145
67,612
70,251
74,870
59,621
57,194
36,109
44,120
69,205
59,187
43,755
63,345
64,085
95,356
80,214
61,899
32,224
36,547
33,367
36,235
24,235
29,270
20,993
123,728
108,307
98,455
98,455108,307123,72820,99329,27024,23536,23533,36736,54732,22461,89980,21495,35664,08563,34543,75559,18769,20544,12036,10957,19459,62174,87070,25167,61262,14543,12428,2046,0483,5615,7699,58313,17216,92921,6585,4517,5829,17012,317000
   > Total Current Assets 
0
0
0
12,161
9,004
6,306
3,413
21,623
16,892
13,131
9,492
5,663
3,459
5,952
28,107
10,991
11,838
18,473
21,932
26,744
13,899
12,589
17,724
25,485
50,245
41,033
26,005
46,096
47,364
77,006
61,845
43,659
15,021
19,450
16,416
19,253
7,519
12,659
8,395
111,213
95,894
86,148
86,14895,894111,2138,39512,6597,51919,25316,41619,45015,02143,65961,84577,00647,36446,09626,00541,03350,24525,48517,72412,58913,89926,74421,93218,47311,83810,99128,1075,9523,4595,6639,49213,13116,89221,6233,4136,3069,00412,161000
       Cash And Cash Equivalents 
0
0
0
11,742
8,599
6,143
3,308
21,162
16,602
11,880
8,815
5,128
3,002
5,461
23,955
2,472
2,180
6,838
10,646
16,121
9,387
5,251
3,609
5,659
45,391
33,391
18,919
38,292
40,435
71,506
54,585
38,469
11,249
16,943
13,172
16,687
6,307
10,180
7,416
110,181
93,426
81,858
81,85893,426110,1817,41610,1806,30716,68713,17216,94311,24938,46954,58571,50640,43538,29218,91933,39145,3915,6593,6095,2519,38716,12110,6466,8382,1802,47223,9555,4613,0025,1288,81511,88016,60221,1623,3086,1438,59911,742000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,629
14,709
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000014,7097,6290000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
650
379
133
187
75
30
3,679
3,396
9,273
8,627
8,249
3,003
5,164
5,242
4,259
3,985
5,957
4,385
5,186
5,118
3,912
4,799
2,383
1,850
1,314
1,919
857
44
1,538
136
35
33
998
99833351361,538448571,9191,3141,8502,3834,7993,9125,1185,1864,3855,9573,9854,2595,2425,1643,0038,2498,6279,2733,3963,6793075187133379650000000000
       Other Current Assets 
0
0
0
360
346
104
105
402
232
542
210
391
250
402
341
703
954
1,260
1,530
1,248
865
1,670
707
777
824
1,544
2,660
2,465
1,750
1,408
2,372
2,682
1,885
1,118
1,290
1,627
1,135
940
844
997
2,435
3,292
3,2922,4359978449401,1351,6271,2901,1181,8852,6822,3721,4081,7502,4652,6601,5448247777071,6708651,2481,5301,260954703341402250391210542232402105104346360000
   > Long-term Assets 
0
0
0
156
166
1,277
2,038
35
37
41
90
106
102
96
97
32,133
50,307
49,139
48,319
48,126
45,722
44,605
18,385
18,634
18,960
18,154
17,750
17,249
16,721
18,350
18,369
18,240
17,203
17,097
16,951
16,982
16,716
16,611
12,598
12,515
12,413
12,307
12,30712,41312,51512,59816,61116,71616,98216,95117,09717,20318,24018,36918,35016,72117,24917,75018,15418,96018,63418,38544,60545,72248,12648,31949,13950,30732,1339796102106904137352,0381,277166156000
       Property Plant Equipment 
0
0
0
39
33
28
41
35
37
41
40
43
39
33
34
45
58
92
587
1,477
1,526
1,496
1,448
1,417
1,741
1,708
1,607
1,530
1,431
1,410
2,695
2,604
2,567
2,507
2,411
2,442
2,176
2,071
1,965
1,882
1,780
1,674
1,6741,7801,8821,9652,0712,1762,4422,4112,5072,5672,6042,6951,4101,4311,5301,6071,7081,7411,4171,4481,4961,5261,477587925845343339434041373541283339000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,292
18,070
16,411
16,411
16,411
16,411
16,411
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
10,502
10,502
10,502
10,502
10,50210,50210,50210,50214,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40916,41116,41116,41116,41116,41118,07014,292000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,664
32,003
32,456
31,239
30,161
27,633
26,595
2,426
2,696
2,292
1,889
1,585
1,161
732
304
38
0
0
0
0
0
0
0
0
0
0
0
00000000000383047321,1611,5851,8892,2922,6962,42626,59527,63330,16131,23932,45632,00317,664000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149
149
149
149
2,227
1,227
1,227
227
181
131
0
131
0
0
0
0
0
0000013101311812271,2271,2272,2271491491491490000000000000000000000000
> Total Liabilities 
0
0
0
38,648
38,688
9,906
38,302
8,574
8,048
7,601
8,996
5,562
3,987
2,912
6,083
15,264
42,926
48,104
49,343
51,750
41,925
38,973
15,113
18,531
18,627
20,620
19,194
30,190
42,497
55,047
57,132
55,556
38,175
38,575
44,282
42,502
31,204
14,575
13,689
224,813
110,458
77,379
77,379110,458224,81313,68914,57531,20442,50244,28238,57538,17555,55657,13255,04742,49730,19019,19420,62018,62718,53115,11338,97341,92551,75049,34348,10442,92615,2646,0832,9123,9875,5628,9967,6018,0488,57438,3029,90638,68838,648000
   > Total Current Liabilities 
0
0
0
4,994
5,751
5,812
6,654
5,850
6,172
6,586
7,496
4,312
2,737
1,662
4,833
11,406
19,045
24,912
26,217
28,135
18,765
17,262
12,160
15,330
14,595
16,571
15,225
26,360
21,674
19,038
19,888
17,893
15,395
18,149
22,114
23,245
22,454
6,005
4,618
215,700
96,397
60,674
60,67496,397215,7004,6186,00522,45423,24522,11418,14915,39517,89319,88819,03821,67426,36015,22516,57114,59515,33012,16017,26218,76528,13526,21724,91219,04511,4064,8331,6622,7374,3127,4966,5866,1725,8506,6545,8125,7514,994000
       Short-term Debt 
0
0
0
1,906
2,729
3,044
3,129
3,208
3,304
3,391
3,190
2,354
1,492
608
0
788
1,050
1,050
1,050
1,050
1,050
1,050
0
0
432
449
426
357
288
219
485
522
524
2,564
6,462
9,296
14,650
536
537
545
548
550
55054854553753614,6509,2966,4622,564524522485219288357426449432001,0501,0501,0501,0501,0501,05078806081,4922,3543,1903,3913,3043,2083,1293,0442,7291,906000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,564
5,930
9,296
14,115
0
0
0
0
0
0000014,1159,2965,9302,564000000000000000000000000000000000
       Accounts payable 
0
0
0
931
722
1,247
1,952
678
591
756
809
1,010
596
327
313
1,299
2,940
1,536
1,446
1,249
1,445
826
2,078
2,726
2,558
1,927
2,574
11,913
3,965
3,568
3,369
3,757
2,164
1,447
2,882
5,565
751
789
446
916
654
1,811
1,8116549164467897515,5652,8821,4472,1643,7573,3693,5683,96511,9132,5741,9272,5582,7262,0788261,4451,2491,4461,5362,9401,2993133275961,0108097565916781,9521,247722931000
       Other Current Liabilities 
0
0
0
1,182
1,717
1,522
54
78
125
35
136
6
9
7
4,521
10,107
2,922
2,546
2,236
2,276
1,567
1,364
10,083
12,604
5,664
5,921
1,452
228
103
20
9
13,614
12,707
13,696
12,682
8,273
7,588
5,216
3,635
214,239
95,195
58,313
58,31395,195214,2393,6355,2167,5888,27312,68213,69612,70713,6149201032281,4525,9215,66412,60410,0831,3641,5672,2762,2362,5462,92210,1074,5217961363512578541,5221,7171,182000
   > Long-term Liabilities 
0
0
0
33,654
32,937
4,094
31,648
8,574
1,876
1,015
1,500
1,250
1,250
1,250
1,250
3,858
23,880
23,193
23,126
23,615
23,160
21,710
2,953
3,201
4,032
4,049
3,969
3,830
20,823
36,009
37,244
37,663
22,780
20,426
22,168
19,257
8,750
8,570
9,071
9,113
14,061
16,705
16,70514,0619,1139,0718,5708,75019,25722,16820,42622,78037,66337,24436,00920,8233,8303,9694,0494,0323,2012,95321,71023,16023,61523,12623,19323,8803,8581,2501,2501,2501,2501,5001,0151,8768,57431,6484,09432,93733,654000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,143
32,483
0
0
0
0
0
10,470
0
0
0
0
0
0
00000010,4700000032,48317,1430000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,955
2,930
2,812
2,682
3,526
4,411
2,535
4,067
3,924
6,971
0
8,750
0
0
0
0
0
000008,75006,9713,9244,0672,5354,4113,5262,6822,8122,9302,9550000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90
111
122
130
0
0
0
0
0
5,158
0
0
0
0
0
0
0000005,158000001301221119000000000000000000000000000
> Total Stockholder Equity
0
0
0
-26,331
-29,518
-2,324
-32,851
13,084
8,881
5,571
587
207
-426
3,135
22,120
27,860
19,219
19,508
20,908
23,121
17,696
18,221
20,996
25,589
50,578
38,567
24,562
33,155
21,588
40,309
23,082
6,343
-5,951
-2,028
-10,915
-6,267
-6,969
14,695
7,304
-101,085
-2,151
21,076
21,076-2,151-101,0857,30414,695-6,969-6,267-10,915-2,028-5,9516,34323,08240,30921,58833,15524,56238,56750,57825,58920,99618,22117,69623,12120,90819,50819,21927,86022,1203,135-4262075875,5718,88113,084-32,851-2,324-29,518-26,331000
   Common Stock
0
0
0
1
18
5
1
9
9
9
9
9
11
14
26
2,687
34
41
41
43
43
44
44
60
75
75
75
89
96
112
113
113
9
9
9
13
14
192
1
1
1
10
101111921413999113113112968975757560444443434141342,6872614119999915181000
   Retained Earnings Total Equity000000-313,77900000-242,970-225,575-208,470-177,79000000000000000000000000000
   Accumulated Other Comprehensive Income -1,658-11,457-11,457000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202,276
241,535
247,067
283,167
0
0
0
0
0
307,499
0
0
0
0
0
0
000000307,49900000283,167247,067241,535202,27600000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
16,742
16,775
46,895
-11,282
66,639
67,576
67,790
68,974
70,233
71,559
76,916
77,168
83,338
87,241
112,126
119,082
128,747
129,546
134,086
135,239
160,936
199,191
200,639
202,276
241,535
247,067
283,167
285,135
290,447
291,244
291,975
292,900
307,499
314,755
341,469
342,437
355,338
355,809
354,332
354,332355,809355,338342,437341,469314,755307,499292,900291,975291,244290,447285,135283,167247,067241,535202,276200,639199,191160,936135,239134,086129,546128,747119,082112,12687,24183,33877,16876,91671,55970,23368,97467,79067,57666,639-11,28246,89516,77516,742000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.